What's Happening?
Researchers at Westlake University in China have developed a high-throughput platform for engineering fast-acting covalent protein therapeutics. This platform aims to address the kinetic mismatch in covalent protein drugs, which are typically cleared
rapidly in vivo while forming slow covalent bonds. The new system combines yeast surface display with chemoselective protein modification, allowing for rapid and irreversible target engagement. The platform has been used to develop a covalent antagonist targeting PD-L1, named IB101, which shows strong antitumor activity in mouse models. Additionally, it has been applied to cytokine engineering, resulting in a covalent IL-18 variant, IB201, which enhances signaling strength and duration. The platform also demonstrated versatility by developing a covalent inhibitor targeting the receptor-binding domain of SARS-CoV-2, showing durable viral neutralization.
Why It's Important?
The development of this high-throughput platform is significant as it overcomes a fundamental limitation in the field of covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform provides a new framework for designing biologics with both rapid kinetics and sustained target engagement. This advancement has broad implications for cancer immunotherapy, antiviral therapy, and beyond, potentially leading to more effective treatments with fewer side effects. The ability to rapidly develop and test new covalent protein drugs could accelerate the pace of drug discovery and development, benefiting patients with hard-to-treat diseases.
